A PK/PD Study of Polyethylene Glycol Loxenatide in Patients With Type 2 Diabetes

Summary

Polyethylene Glycol Loxenatide (PEX168) is a new human glucagon-like peptide 1 (GLP-1) analogue that created on the basis of the Exenatide and modified by polyethylene glycol (PEG). This study aims to evaluate the effective therapeutic concentration range of PEX168, also decided to observe safety and PK/PD correlation by long-term continuous administration.

Timeline

Start

2012-05

Primary completion

2013-08

Completion

2013-10

Drugs

Indications